Science Magazine Once Again Names Regeneron the Best Company to Work For



Regeneron Pharmaceuticals, Inc.
October 27, 2016 at 2:05 PM EDT

Science Magazine Once Again Names Regeneron the Best Company to Work For

TARRYTOWN, New York, Oct. 27, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Science magazine has ranked the company as the world's number one employer in its annual survey of the biotech and pharmaceutical industry. Regeneron has been ranked first for four of the past six years, with second place rankings in 2015 and 2011.

"This recognition goes to the heart of who we are at Regeneron - a science-driven company with incredibly passionate people working relentlessly to bring new medicines to people with serious diseases," said George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories and Chief Scientific Officer, Regeneron. "Our success is a direct result of our unique culture of innovation and collaboration. We've grown dramatically over the past five years to more than 5,000 employees, and our top priority is maintaining an environment that empowers people to do their best work and have the best possible time doing it."

The Science and Science Careers 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics.

Survey respondents rated Regeneron highly based on 23 characteristics, including treating employees with respect and loyalty, operating in a manner that is socially responsible, adapting effectively to change, and producing important, quality research. Regeneron earned particularly high marks among survey respondents for being an innovative leader in the industry and 'having a clear vision' for future success.

According to Science, the 2016 global survey results were based on nearly 6,000 responses from North America (56 percent), Europe (28 percent) and the Asia/Pacific Rim (12 percent).

For the complete feature including individual company rankings, please visit

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit or follow @Regeneron on Twitter.

Media Contact at Regeneron:
Alexandra Bowie, Tel. 914.847.3407

To view the original version on PR Newswire, visit:

SOURCE Regeneron Pharmaceuticals, Inc.



News Provided by Acquire Media